In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Myocardial constructive work is a predictor of long-term outcomes in patients with heart failure undergoing cardiac resynchronization therapy.

Session Poster Session 7

Speaker Elena Galli

Congress : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : Tissue Doppler, Speckle Tracking and Strain Imaging
  • Session type : Poster Session
  • FP Number : P6470

Authors : E Galli (Rennes,FR), A Hubert (Rennes,FR), V Le Rolle (Rennes,FR), A Hernandez (Rennes,FR), O Smiseth (Oslo,NO), P Mabo (Rennes,FR), C Leclercq (Rennes,FR), E Donal (Rennes,FR)

15 views

Authors:
E. Galli1 , A. Hubert1 , V. Le Rolle2 , A. Hernandez2 , O. Smiseth3 , P. Mabo1 , C. Leclercq1 , E. Donal1 , 1University Hospital of Rennes, Cardiology - Rennes - France , 2University of Rennes, Laboratoire Traitement du Signal et de l'Image, INSERM U-1099 - Rennes - France , 3University of Oslo - Oslo - Norway ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1371-1372

Background: Myocardial constructive work (CW) assessed by pressure strain loops (PSLs) is an independent predictor of cardiac resynchronization therapy response (CRT+).

Purpose of the study: To assess the role of CW in the prediction of long-term outcome in patients undergoing CRT.

Methods: 2D- and speckle-tracking echocardiography were performed in 166 CRT candidates (mean age: 66±10 years, males: 69%) before CRT implantation and at 6-month follow-up. Left-ventricular (LV) end-systolic volume reduction >15% at 6-month follow-up defined CRT+ and occurred in 48 (29%) patients.

Results: After a median 4-year FU (range: 1.3–5 years), all-cause death occurred in 28 patients (17%), cardiac death in 14 (8%). At Cox-regression analysis, CW emerged as an independent predictor of outcome (Table 1). A CW cut-off of 888 mmHg% (AUC 0.71, p=0.007 and AUC 0.67, p=0.004 for cardiac and all-cause mortality) was associated with an increased mortality risk (Figures 1, 2).

Conclusions: The estimation of LV-CW is a relatively novel tool, which allows the prediction of long-term outcome in CRT candidates.

Univariable analysisMultivariable analysis
Cardiac deathHR95% CIp-valueHR95% CIp-value
Age, per year1.08(1.01–1.15)0.021.07(1.00–1.15)0.04
Ischaemic disease3.99(1.34–11.94)0.012.33(0.71–1.15)0.16
NYHA >21.39(0.46–4.24)0.56
LBBB0.87(0.27–2.77)0.81
LVEF, per %0.99(0.92–1.08)0.89
Septal flash0.19(0.06–0.62)0.0060.48(0.12–1.95)0.30
CW, per mmHg%0.99(0.99–1.00)0.040.99(0.99–1.00)0.04
CRT-response0.26(0.09–0.78)0.020.68(0.18–2.57)0.58
All-cause death
  Age, per year1.05(1.01–1.09)0.011.06(1.01–1.10)0.01
  Ischaemic disease2.69(1.27–5.66)0.0091.94(0.86–4.39)0.11
  NYHA>21.86(0.80–4.30)0.15
  LBBB0.85(0.34–2.12)0.72
  LVEF, per %0.98(0.93–1.04)0.50
  Septal flash0.39(0.19–0.83)0.020.87(0.34–2.22)0.77
  CW, per mmHg%0.99(0.99–1.00)0.030.99(0.99–1.00)0.03
  CRT-response0.36(0.17–0.76)0.0070.24(0.24–1.43)0.59

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are